Advice

Following a full submission

bevacizumab (Avastin) is not recommended for use within NHS Scotland in combination with fluoropyrimidine-based chemotherapy for treatment of patients with metastatic carcinoma of the colon or rectum. In a randomised trial standard chemotherapy plus bevacizumab showed a small benefit over standard chemotherapy alone in terms of progression-free survival.

However, the manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.

Download detailed advice100KB (PDF)

Download

Medicine details

Medicine name:
bevacizumab (Avastin)
SMC ID:
469/08
Indication:
In combination with fluoropyrimidine-based chemotherapy is indicated for treatment of patients with metastatic carcinoma of the colon or rectum.
Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Superseded
Date advice published
09 June 2008
Additional notes

NICE MTA Advice:  SMC Advice is superseded by National Institute for Health and Clinical Excellence (NICE) Multiple Technology Appraisal (MTA)